This article looks at the biggest offenders in the shrinkflation game.

After experimentation with LLMs, engineering leaders are discovering a hard truth: better models alone don’t deliver better ...

Mylan’s long-awaited rival for Teva’s blockbuster multiple sclerosis drug Copaxone has been approved in the US, putting a large chunk of the Israeli firm’s revenues at risk. The timing could not have ...